VTRS — Viatris Inc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1792044 ·
Last close
$17.83
Market Cap
$20.48B
52W High
$18.25
52W Low
$9.15
ADV30
7,900,777
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 3,756,800,000 1,456,500,000 73,700,000 -118,800,000 35,044,600,000 886,500,000 20,784,200,000
Mar 2026 3,517,000,000 1,157,200,000 -20,200,000 176,400,000 36,834,600,000 1,804,200,000 22,176,900,000
Dec 2025 3,703,600,000 1,147,900,000 -157,500,000 -340,100,000 37,193,100,000 1,322,400,000 22,481,800,000
Sep 2025 3,759,900,000 1,371,500,000 234,500,000 -128,200,000 37,920,400,000 975,300,000 22,702,800,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$2,168,700,000
Investing CF
$-85,200,000
Financing CF
$-1,030,700,000
CapEx
$-512,900,000
Dividends Paid
$-557,500,000
Buybacks
$-325,100,000
EPS Diluted TTM
$-0.26
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-211,900,000
Inventory
$3,927,000,000
Receivables
$3,742,000,000
ST Investments
$596,000,000
EBIT TTM
$-339,400,000
Pretax Income TTM
$-815,300,000
Interest Exp TTM
$475,900,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$14,737,300,480
EBITDA
$4,292,499,968
Free Cash Flow
$2,677,337,600
Enterprise Value
$31,076,435,968
Total Cash
$1,510,499,968
Total Debt
$13,623,700,480
Shares Out
1,148,590,864
Trailing EPS
$-0.37
Book Value
$12.59
ROE
-2.8%
ROA
2.7%
Div Yield
2.91%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 14,299,900,000 253,500,000 -3,514,900,000 37,193,100,000 22,481,800,000 14,711,300,000 2,315,900,000
Dec 2024 14,739,300,000 710,300,000 -634,200,000 41,500,900,000 22,865,400,000 18,635,500,000 2,302,900,000
Dec 2023 15,426,900,000 1,563,400,000 54,700,000 47,685,500,000 27,218,100,000 20,467,400,000 2,900,000,000
Dec 2022 16,262,700,000 1,655,700,000 2,078,600,000 50,022,200,000 28,949,900,000 21,072,300,000 2,999,000,000

TTM Snapshot

Revenues TTM
$15,025,600,000
NetIncome TTM
$-2,261,300,000
OpCashFlow TTM
$0
Assets (Latest)
$37,193,100,000
Forward EPS
$2.66

Max Pain — expiry 2026-10-16

max pain strike: $16.00 · spot: $17.88 · call oi: 12,830 · put oi: 3,821
Expected Move to 2026-10-16: ±$0.90 (5.03%) — implied range $16.98 – $18.78 · ATM straddle on $18.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
UTHR UNITED THERAPEUTICS Corp $20.39B $475.45 —
GMAB GENMAB A/S $21.72B $35.32 —
INSM INSMED Inc $25.73B $117.83 —
ROIV Roivant Sciences Ltd. $25.86B $35.80 —
RPRX Royalty Pharma plc $25.92B $58.21 —

News headlines (Yahoo Finance, 1h cache)

Is Viatris Stock Outperforming the S&P 500?
2026-09-24 10:57 · Yahoo
Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business?
2026-09-21 00:03 · Yahoo
Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks
2026-09-02 13:15 · Yahoo
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
2026-08-28 09:15 · Yahoo
Viatris' China Policy Concerns Overstated, UBS Says
2026-08-19 16:16 · Yahoo
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
2026-08-13 23:03 · Yahoo
Viatris sues Novo Nordisk over generic Wegovy patent dispute
2026-09-25 19:53 · Yahoo
3 US Stocks That Could Gain If Buyers Shift Away From India
2026-09-19 17:14 · Yahoo
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
2026-09-16 10:59 · Yahoo
3 Healthcare Stocks That Fall Short
2026-09-14 15:23 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.